Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimalarials and ophthalmologic safety

A J Olansky

    Journal of the American Academy of Dermatology
    |January 1, 1982
    PubMed
    Summary

    Antimalarial drugs effectively treat lupus erythematosus. Retinal toxicity concerns led to reduced use, but proper dosage and eye exams prevent damage, allowing safe and effective lupus treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Ehlers-Danlos syndrome: recognition, characterization, and importance of a milder variant of the classic form. A preliminary study.

    Journal of the American Academy of Dermatology·1988
    Same author

    A better stain for Tzanck smears.

    Journal of the American Academy of Dermatology·1983
    Same author

    Bullous systemic lupus erythematosus.

    Journal of the American Academy of Dermatology·1982
    Same author

    Superficial ulcerating necrobiosis in rheumatoid arthritis. A variant of the necrobiosis lipoidica-rheumatoid nodule spectrum?

    Archives of dermatology·1982
    Same author

    Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model.

    Annals of internal medicine·1980

    Area of Science:

    • Dermatology
    • Ophthalmology
    • Rheumatology

    Background:

    • Antimalarial drugs were recognized for treating lupus erythematosus in 1951.
    • Fear of retinal toxicity and alternative treatments limited antimalarial use by 1966.
    • Renewed interest in antimalarials stems from evident toxicities of alternative therapies.

    Purpose of the Study:

    • To address misconceptions regarding antimalarial drug retinal toxicity.
    • To highlight that retinal toxicity can be avoided with proper management.
    • To reaffirm the therapeutic efficacy of antimalarials in lupus treatment.

    Main Methods:

    • Historical review of antimalarial drug use in lupus.
    • Analysis of studies on antimalarial retinal toxicity.
    • Evaluation of dosage and ophthalmologic follow-up protocols.

    Main Results:

    • Irreversible retinal toxicity from antimalarials is preventable.
    • Judicious daily dosage and regular ophthalmologic follow-up mitigate risks.
    • Therapeutic efficacy of antimalarials can be maintained safely.

    Conclusions:

    • Antimalarial drugs remain valuable for lupus erythematosus treatment.
    • Concerns about retinal toxicity are manageable with current guidelines.
    • Safe and effective use of antimalarials in lupus is achievable.

    Related Experiment Videos